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Abstract. 
Renal cell carcinoma (RCC) is a highly lethal genitourinary malignancy due to infrequent 
early diagnosis, which responds poorly to conventional immune therapy, chemotherapy or ra-
diotherapy in metastatic disease. There have been great advances in the understanding of the 
molecular mechanisms of RCC in recent years, especially with regards to dysfunction of the 
Von Hippel–Lindau tumor suppressor gene in clear cell type RCC. This dysfunction has been 
shown to result in the activation of downstream angiogenesis related genes such as vascular 
endothelial growth factor. Treatment targeting this molecular pathway has been shown to im-
prove patient prognosis and has become the standard treatment for metastatic clear cell RCC. 
Herein, we report a case of advanced and metastatic RCC initially presenting as low-back 
pain, but without the typical symptoms. Physical, laboratory and imaging examinations re-
vealed a large left kidney tumor and multiple metastases to the liver and bones. The patient re-
ceived oral tyrosine kinase inhibitor target therapy with a good tumor response.  
Treatment of RCC has entered the era of molecular target therapy, however some issues 
still need to be addressed, such as the safety issue of tyrosine kinase inhibitor and role of cy-
toreductive surgery. We also review related articles and have some discussion. 
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中文摘要 
  腎細胞癌是一個高致命性的泌尿系統惡性腫瘤，原因包含了早期疾病不易診斷以及
晚期轉移性腎細胞對傳統化學治療、免疫治療及放射線治療有高度抗性。但近幾年對腎
細胞癌的分子致病機轉有更透徹之了解，尤其是透明細胞型腎細胞癌具有 VHL 抑癌基因
的異常，導致下游血管內皮生長因子等與血管新生有關的基因活化而造成腫瘤。針對上
journal homepage:www.cos.org.tw/web/index.asp
台灣癌症醫誌 (J. Cancer Res. Pract.) 1(1), 63-69, 2014
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 述與血管新生有關分子接受器之標靶治療，改善病人的預後，也改變了轉移性腎細胞癌
之治療方式。 
    我們報告一位年輕的女性被診斷出轉移性的腎細胞癌，但是初始的表現是下背痛，
經過一系列檢查才發現有一個巨大的左側腎臟腫瘤以及多處肝和骨頭的轉移。這位病人
使用口服標靶治療來控制病情，目前仍然在治療中。 
    雖然腎細胞癌的治療進入了分子標靶的新時代，但還是有一些值得探討的課題，我
們也回顧相關的一些文獻。 
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INTRODUCTION 
The treatment of metastatic renal cell carcinoma 
(RCC) has greatly advanced in recent years, primarily 
in the understanding of molecular pathogenesis. The 
clear cell subtype of renal cell carcinoma is character-
ized by mutations of the Von Hippel-Lindau (VHL) 
gene, leading to activation of downstream vascular 
endothelial growth factor (VEGF) and contributing to 
tumor progression and metastasis. The use of oral ty-
rosine kinase inhibitors (TKI) to block this signaling 
pathway has revolutionized the treatment of metastatic 
clear cell type RCC. 
Herein, we report a case of a young female patient 
who presented with lower limb weakness. After a se-
ries of examinations, clear cell-type RCC was diag-
nosed. In addition, multiple metastases to the liver and 
bone were also found. The patient received oral TKI 
as the first line treatment. 
 
CASE REPORT 
A 35-year-old female presented to the neurosur-
gery outpatient department for progressive low-back 
pain complaining of lower leg weakness for two 
months. She denied a significant medical history. Up-
on neurological examination, the muscle power of her  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. T2-weighted magnetic resonance imaging of 
the lumbar spine showed multiple bone le-
sions. Pathologic fracture of the first lumbar 
spine with root compression was noted (Pan-
el A). Transverse view showed a heteroge-
neous and hyper-vascular mass lesion de-
veloping from the vertebral body (Panel B) 
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Figure 2. Positron emission tomography-computed tomography revealed a large left kidney tumor and another 
large liver mass, both with high 2-deoxy-2-fluoro-D-glucose (FDG) uptake (Panel A). Multiple bone 
lesions on the left rib (Panel B) and vertebral body (Panel C) were also noted 
 
 
legs was 3-4 with normal deep tendon reflex. Sensory 
examinations of both legs were also normal; however, 
a subsequent physical examination revealed mild left 
flank knocking pain without any obvious mass or 
lymph nodes. She denied weight loss, fever, cough, 
sputum, nausea, vomiting, or changes in bowel move-
ments. 
Magnetic resonance imaging of the thoracic and 
lumbar spine showed multiple osteolytic bone lesions 
with a suspected pathologic fracture over the first to 
third lumbar spines (Figure 1). A positron emission 
tomography-computed tomography (PET-CT) scan 
was performed to determine the origin and disease 
extent, which revealed a large tumor (approximately 9 
cm in diameter) on the left kidney and multiple bone 
metastases, including the lumbar spine, left rib, and 
right clavicle. Another large mass (about 10 cm in 
diameter) was also found in the liver, with some 
smaller intra-hepatic lesions (Figure 2). The impres-
sion was malignancy with spine metastasis and she 
was admitted to the hematology/oncology ward.  
The patient underwent a computed tomography 
(CT)-guided biopsy to evaluate the spinal and left 
kidney lesions. Pathology of the left kidney (Figure 3) 
revealed tumor cells with eosinophilic and granular 
cytoplasm, and clear cells, suggesting clear cell type 
RCC. Pathology of the spinal lesion also showed me-
tastasis of clear cell type RCC. Laboratory tests 
showed anemia (hemoglobin, 9.2 g/dl) and slightly 
elevated lactate dehydrogenase (386 IU/L), while the 
total calcium level was within normal range (9.5 
mg/dl). The Karnofsky performance status score was 
80%. 
The patient received oral tyrosine kinase inhibitor 
treatment with sunitinib (50 mg once daily for 4 
weeks, followed by 2 weeks without treatment). 
Laminectomy and trans-pedicle screw fixation were 
performed for the spinal lesion during the 29th to 
42nd days (drug vacation) of the second treatment 
cycle in another hospital. The surgical wound healed 
well after the operation, and sunitinib was restarted 
one week after the operation. Repeat CT after three 
months of treatment showed a smaller left kidney tu-
mor (about 7 cm in diameter) and liver metastases (8 
cm in diameter), suggesting a stable disease after ap-
plying a Response Evaluation Criteria in Solid Tumors 
(RECIST) assessment. Another CT after six months of 
treatment also showed stable disease.  
In terms of adverse effects, the patient suffered 
from mild fatigue (grade 1) and leucopenia (grade 2) 
during treatment. She resumed normal daily activities 
and was regularly followed-up at the hematology/  
oncology outpatient department. 
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Figure 3. Hematoxylin and eosin staining (200X) revealed tumor cells growing in solid and trabecular patterns, 
with a regular network of thin-walled vessels. The tumor cells had hyper-chromatic nuclei and eosino-
philic or clear cytoplasm (Panel A). Immuno-histochemistry was positive for cytokeratin (Panel B, left) 
and vimentin (Panel B, right). These features are consistent with renal cell carcinoma, clear cell type 
 
 
DISCUSSION 
There are several histologic subtypes of RCC, the 
most common of which is the clear cell type. This 
type is genetically characterized by mutations of the 
Von Hippel-Lindau (VHL) gene, a tumor suppressor 
gene linked to the regulation of hypoxia-inducible 
factor-α (HIF-α) [1]. With VHL gene mutations, 
HIF-α is stabilized and accumulates, which then 
up-regulates down-stream VEGF contributing to tu-
mor progression and metastasis [2-4]. Mutations of 
the VHL gene are found in 92% of clear cell RCC pa-
tients [5], so the VHL gene-related molecular pathway 
has emerged as a therapeutic target for clear cell RCC. 
This report is of a patient with advanced and met-
astatic clear cell RCC with an atypical initial presenta-
tion. However, the classic presentation of pain, hema-
turia, and flank mass is seen in only a minority of pa-
tients. In previous studies, renal carcinoma has been 
reported to remain clinically occult for most of its 
course, and approximately 30% of patients are diag-
nosed with renal carcinoma with metastatic disease. 
The lungs are the most common metastatic site, fol-
lowed by soft tissues, the bones, and liver [6]. This 
patient had suspected metastatic bone lesions first, 
then she later received a PET/CT scan to evaluate the 
origin of malignancy. However, we have to make clear 
that the most important role of PET/CT in clinical 
practice is to determine the extent of malignancy. For 
metastasis of unknown origin, PET-CT may have 
some value when pathology has offered limited in-
formation. 
The management of stage 4 clear cell RCC has 
advanced significantly in recent years, mainly due to a 
better understanding of its genetic mechanism and the 
development of associated target therapies. In the past, 
the first-line systemic treatments were interferon-  
alpha (IFN-α) or interleukin-2 immunotherapy [7,8]. 
Currently, targeted therapy utilizing TKI is used 
widely as first- and second-line treatments. 
Before selecting TKI as initial treatment, risk 
stratification of patients is important. The Memorial 
Sloan-Kettering Cancer Center (MSKCC) model has 
been utilized to evaluate and predict outcomes of 
MRCC patients since the immune therapy era [9]. And 
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 this classification system is still in use in many current 
clinical trials. This model classifies patients according 
the presence or absence of 5 adverse prognostic fac-
tors (Table 1); more adverse factors indicate a poorer 
prognosis. The patient in the current report had 2 ad-
verse prognostic factors and was classified as being at 
immediate risk.  
In a large phase III multi-center trial mainly enrol-
ling favorable and immediate risk group, sunitinib 
showed superiority in objective response rate (31% vs. 
6%, P<0.001), progress-free survival (II months vs. 5 
months, P < 0.001), and overall survival (26.4 months 
vs. 21.8 months, P = .051) compared to IFN-α treat-
ment. In terms of treatment-related side effects, grade 
3 or 4 fatigue was found to be significantly higher 
among patients in the interferon-α group (12% vs. 7%, 
P < 0.05). Grade 3 or 4 hematological adverse effect 
such as leukopenia, neutropenia, and thrombocytope-
nia were noted more often in the sunitinib group (P < 
0.05 for all comparisons). The evaluation of health- 
related quality of life revealed a significantly better 
result in the sunitinib group (P < 0.001) [10,11]. Based 
on the result of this trial, sunitinib was the appropriate 
first line treatment in both the favorable and immedi-
ate risk groups. 
The patient in the current report received a spinal 
operation during sunitinib treatment, and this raised 
concerns in terms of surgical safety because sunitinib 
is a multitargeted TKI with anti-VEGF activity. An-
other widely used anti-VEGF agent, bevacizumab, has 
been found to have the adverse effects of wound heal-
ing or wound bleeding in previous articles. One of the 
possible mechanisms is a decreased ability of endo-
thelial cells to respond to injury when VEGF is inhib-
ited. Patients receiving bevacizumab treatment should 
therefore wait at least 6 to 8 weeks after cessation of 
treatment before undergoing surgery because the 
half-life is around 20 days [12]. However, there does 
not seem to be a significant increase in delayed wound 
healing or wound bleeding after surgery in patients 
with renal cell carcinoma or gastrointestinal stromal 
tumors undergoing sunitinib treatment [13-15]. This 
difference may be attributable to the shorter half-life 
of sunitinib (41 to 86 hours) [16]. 
This patient suffered from a huge tumor burden of 
primary renal tumor and liver metastasis, so we also 
reviewed the literature about cytoreduction. The role 
of cyto-reductive nephrectomy is controversial in the 
era of TKI therapy, because TKI has a different anti- 
tumor mechanism compared to immunotherapy. In a 
retrospective study, patients with metastatic RCC re-
ceiving VEGF treatment had prolonged overall sur-
vival when they received cyto-reductive nephrectomy 
[17]. However, another retrospective study showed no 
significant benefits of cyto-reductive nephrectomy 
[18]. In a recently published multi-center retrospective 
analysis, patients with clear cell type RCC treated 
with TKI alone or combined with local treatments 
(such as surgery, radiotherapy or radiofrequency abla-
tion) for metastatic sites were able to achieve com-
Table 1. Memorial Sloan-Kettering Cancer Center (MSKCC) mode 
1. Poor Karnofsky performance status (< 80%) 
2. Time from diagnosis to treatment with IFN-α less than 12 months 
3. High “corrected” serum calcium level (> 10 mg/dl) 
4. Low hemoglobin level (< lower limit of normal) 
5. High serum lactate dehydrogenase (higher than 1.5 times of the upper limit of normal) 
MSKCC risk stratification model 
Favorable-risk: 0 risk factors 
Intermediate-risk: 1 or 2 risk factors 
Poor-risk: 3 or more risk factors 
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 plete remission [19]. In that study, patients with com-
plete remission belonged to a different prognostic 
group and had different metastatic sites. However, all 
of the patients enrolled had undergone nephrectomy 
before TKI treatment. There is a paucity of data from 
prospective studies, and associated clinical trials are 
still ongoing. 
In conclusion, we report a case of metastatic RCC 
with large primary and metastatic tumors, with a rela-
tively indolent initial presentation. The patient was 
responsive to TKI treatment, though issues such as the 
role of cyto-reductive surgery or local treatment re-
quire further investigation. More prospective studies 
are warranted to address these questions and further 
improve patient management and outcomes. 
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